Mechanisms and treatment of cardiovascular disease in Williams-Beuren syndrome

Barbara R. Pober
*Harvard Medical School*

Mark Johnson
*Washington University School of Medicine in St. Louis*

Zsolt Urban
*Washington University School of Medicine in St. Louis*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**


This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Williams-Beuren syndrome (WBS) is a microdeletion disorder caused by heterozygous loss of approximately 1.5-Mb pairs of DNA from chromosome 7. Patients with WBS have a characteristic constellation of medical and cognitive findings, with a hallmark feature of generalized arteriopathy presenting as stenoses of elastic arteries and hypertension. Human and mouse studies establish that defects in the elastin gene, leading to elastin haploinsufficiency, underlie the arteriopathy. In this review we describe potential links between elastin expression and arteriopathy, possible explanations for disease variability, and current treatment options and their limitations, and we propose several new directions for the development of nonsurgical preventative therapies based on insights from elastin biology.

Williams-Beuren syndrome (WBS, also referred to as Williams syndrome; OMIM 194050) was first recognized as a clinical syndrome, separate from other developmental disability syndromes, because of a unique constellation of cardiovascular (CV) abnormalities. In this review, we describe these characteristic abnormalities, the considerable progress that has been made in understanding their etiology and pathophysiology, and new insights gained into underlying molecular pathways. Finally, we consider currently available therapeutic approaches and opportunities to develop new treatment options.

**Overview of WBS**

In 1961, J.C.P. Williams described four patients and proposed that “the association of supravalvular stenosis with the physical and mental characteristics here described may constitute a previously unrecognized syndrome” (1). Shortly thereafter A.J. Beuren reported eleven new patients (2), and the condition has fittingly borne the eponym Williams-Beuren syndrome ever since.

WBS affects approximately 1/10,000 individuals, is found worldwide among all racial and ethnic groups, and displays multi-system medical and nonmedical problems (3–5). In 1993 the genetic cause of WBS, a chromosomal microdeletion, was reported (6), and this knowledge permitted development of a laboratory-based diagnostic test, so the diagnosis no longer rests on clinical criteria only. The most widely used method to confirm the diagnosis has been FISH, but DNA dosage techniques such as quantitative PCR, multiplex ligation-dependent probe amplification, and chromosomal microarray, also known as comparative genomic hybridization, may soon become confirmatory tests of choice.

**Non-CV clinical features of WBS.** Persons with WBS have a subtle but distinctive facial appearance that changes with age (Figure 1) (3). Their linear growth is usually smaller than that of siblings or healthy, age-matched controls. Though infants and young children tend to be thin, or even underweight, many WBS adults are overweight (3, 7, 8).

Endocrine abnormalities are commonly reported and include hypercalcemia, abnormal glucose metabolism, and (subclinical) hyperthyroidism. The precise frequencies, etiologies, natural histories, and best treatments of these endocrine problems remain to be determined. Other common findings include dental anomalies (small, abnormally shaped teeth, absent teeth, malocclusion), gastrointestinal dysmotility (reflux, constipation), diverticular disease, musculoskeletal anomalies (joint stiffness, scoliosis), sensorineural hearing loss, genitourinary anomalies (urinary frequency, bladder diverticuli), and neurological problems (abnormal tone, hyperreflexia, and cerebellar findings) (3, 7, 9, 10).

Persons with WBS have intellectual handicaps that generally meet the definition of mild to moderate mental retardation on standardized testing. The average full-scale IQ is reported to be 55–60, but a fairly broad range exists, extending from 40–90 (11). Particularly notable is the pattern of intellectual peaks and valleys, referred to as the Williams syndrome cognitive profile, with relative strengths in selected language domains and a prominent weakness in the visuospatial domain (12). Persons with WBS display characteristic personality and emotional traits. Their generally social and friendly demeanor coexists with anxiety (especially anticipatory anxiety), phobias, and perseverative tendencies (i.e., repetitive thoughts or behaviors) (7, 13).

**Molecular genetics of WBS.** The etiology of WBS, a mystery for more than 30 years after its initial description, is now known to be a contiguous gene deletion or microdeletion syndrome at chromosome 7q11.23. Although the chromosomal location is unique, the mechanism of origin is comparable with that of other microdeletion disorders, namely, a deleted genomic interval resulting from nonallelic homologous recombination (NAHR) (14).

The locus for WBS was found through the study of a phenotypically overlapping disorder. Specifically, disruption of the elastin (ELN) gene was identified as the cause of the condition known as familial supravalvular aortic stenosis (familial SVAS) syndrome (OMIM 190750).
185500) by application of linkage analysis and gene sequencing, and by cloning of a chromosome 7q11.2 translocation breakpoint, in selected familial SVAS kindreds (15, 16). Given similar vascular pathologies in familial SVAS and in WBS, study of the ELN gene was undertaken, and deletion of an ELN allele was identified as the cause of WBS (6). Subsequent characterization of the deleted interval, now referred to as the WBS critical region (Figure 2), reveals the following (17–19): (a) 90%–95% of patients clinically diagnosed with WBS have an approximately 1.55-Mb deletion associated with loss of 26–28 genes; (b) 5%–8% of clinically diagnosed WBS patients have a slightly larger, approximately 1.84-Mb pair deletion associated with loss of 28 genes; (c) the deleted intervals are flanked by highly homologous stretches of DNA, organized into a single centromeric duplicon and two telomeric duplicons; (d) each duplicon contains genes, pseudogenes, and clusters of related genes; (e) the duplicons predispose to NAHR through intra- or inter-chromosomal exchange during meiosis; and (f) the deletion arises with equal frequency on either the maternally or the paternally inherited chromosome 7 homolog.

Different breakpoints in the medial block of telomeric repeats determine whether neutrophil cytosolic factor 1 (NCF1) and general transcription factor II I repeat domain–containing 2 (GTF2IRD2) are deleted or not. Several of the deleted genes in patients with WBS are depicted in Figure 2. As this review focuses on CV aspects of WBS, our discussion will emphasize the ELN gene and consequences resulting from its functional loss. For a complete list and description of the genes constituting the WBS critical region, the reader is directed to ref. 20.

Loss of an ELN allele is the single most important genetic change responsible for the CV problems of WBS. The ELN gene encodes a precursor protein, tropoelastin. Multiple isoforms of tropoelastin are generated via alternative splicing, secreted into the extracellular matrix, deposited onto a preformed network of fibrillin microfibrils, and are cross-linked by the lysyl oxidase family of enzymes (21). This process of elastic fiber assembly requires the coordinat

Figure 1
Distinctive facial appearance of persons with WBS. Young child with WBS at 15 months (A) and 3 years (B). Note subtle characteristic facial features including wide mouth, full cheeks, long philtrum, small nose, and delicate chin. (C) At left, the same individual depicted in A and B at 21 years of age. At right, another individual with WBS at 28 years of age. Note persistence of wide mouth, full lips, and delicate chin in adults with WBS.

The most common pathological consequence of chromosome 7q11.23 duplicon–mediated NAHR is WBS (e.g., deletion of the intervening sequence). However, duplication of the interven

CV clinical features of WBS
CV disease, particularly an arteriopathy consisting of stenoses of medium- and large-sized arteries, is the hallmark of WBS. In early case reports and case series, the diagnosis was primarily established

by cardiologists evaluating patients for a heart murmur, which usually was diagnosed as SVAS on cardiac imaging or through catheterization and/or surgery (1, 35).

The prevalence of CV abnormalities in 423 patients from nine selected international series published in the last two decades is shown in Table 1 (36–44). Many patients have multiple CV clinical findings. Although the vascular stenoses of WBS predominantly affect the supravalvular aortic (Figure 3) and pulmonary regions, lesions located elsewhere also occur, primarily but not exclusively affecting the vascular branch points. The wide range of published prevalence reflects the age-dependent frequency of clinical features, variable study methods, especially the modality used to ascertain specific clinical features, and biases in case ascertainment. Spontaneous improvement in pulmonary arterial stenosis over time has been well established, whereas SVAS may progress especially in the first five years of life (36, 38–40, 45, 46). Prospective use of echocardiographic dimensions in one study found a 100% frequency of SVAS but only a 3% frequency of pulmonary arterial stenosis (37). A much higher frequency of pulmonary arterial stenosis (77%–83%) was found in two series of patients, all of whom had undergone at least one cardiac catheterization (36, 39). With improved noninvasive cardiac imaging, valvular abnormalities, particularly of the mitral valve, are being detected with increasing frequency (42).

Figure 2
The WBS critical region. The chromosome 7q11.23 microdeletion, with the loss of 26–28 genes, that is responsible for WBS. Selected genes are labeled. Duplicons predispose to NAHR. More than 90% of WBS patients have the ~1.55-Mb pair deletion extending from FKB6 to GTF2I1, while approximately 5% have the slightly larger deletion of 1.84-Mb pairs. Very rare patients have atypical deletions smaller than the common deletion. Schematics of atypical deletions are shown on right and include a very small deletion encompassing ELN and an adjacent gene; a typical centromeric breakpoint but not the common telomeric breakpoint; and a typical telomeric breakpoint but not the typical centromeric breakpoint. Not all genes are shown; see ref. 20 for a complete list of genes. WBSCR, WBS critical region.
Patients with WBS are at a higher risk of sudden death. Wessel et al. found a risk of 1/1,000 patient years with five cases of sudden death, a 25- to 100-fold increase compared with the normal population (54). Death secondary to myocardial infarction has been detailed in three patients (55, 56). In another report of ten WBS patients with sudden death, pathologic findings suggest that coronary artery stenosis and severe biventricular outflow tract obstruction are mechanisms for myocardial ischemia and arrhythmia (57). Many of the deaths occurred with anesthesia/sedation (often with cardiac catheterization), suggesting that decreased cardiac output from anesthetic agents in concert with coronary artery abnormalities altered myocardial perfusion.

A wide variation in the prevalence of systemic hypertension is shown in Table 1 and is likely due the methodological variations of the type described in the first paragraph of this section. Although more commonly found in adults, hypertension can develop during childhood (58, 59). Three recent studies using 24-hour ambulatory monitoring found hypertension in 40%–70% of patients (59–61), though the etiology of hypertension is not fully known and in most cases is idiopathic. Only a small minority of patients have overt renovascular disease, such as renal artery stenosis or diffuse aortic narrowing (47, 58), but all have vascular abnormalities at the histological level, which will be detailed below.

In one study, infantile hypercalcemia predicted hypertension, but no relationship was found between blood pressure and patients reported to be frequently anxious (59). Others have pointed out that “white coat” hypertension, defined as elevated office blood pressure but normal ambulatory blood pressure (62), is frequent in the general pediatric population. Accordingly, it should be considered in WBS before diagnosing bona fide hypertension, given the high frequency of anxiety disorders in these individuals. The Coanda effect (the tendency of a jet stream to adhere to a wall) from SVAS may cause higher blood pressure only in the right arm (63). Arterial wall thickening seen with intravascular ultrasound imaging in humans has led to the hypothesis that decreased compliance of the arterial tree is a factor in hypertension in WBS (64). A later ultrasound study of the common carotid in 21 patients with WBS confirmed increased intima-media thickness but found no difference in compliance compared with controls (65).

Other cardiac defects are occasionally observed in WBS. Ventricular septal defects, typically small, were found in 0%–14% of the series described in Table 1. Single cases of more complex defects such as tetralogy of Fallot (malalignment ventricular septal defect with right ventricular outflow obstruction) and atrioventricular canal are reported (40, 66). Mild left ventricular myocardial abnormalities in young patients with WBS in the absence of clinically significant outflow tract obstruction (67) parallels the mouse model findings (68). Cerebral arterial disease with stroke are described infrequently in WBS (69, 70), but the true frequency of intracranial vascular stenoses is not known.

Vascular pathology
Arterial abnormalities in WBS include localized or diffuse narrowing of elastic arteries. Diagnostic imaging (64, 71) and pathological studies (72, 73) have both demonstrated generalized arterial wall thickening even in nonstenotic regions of the arterial tree (Figure 4). These nonstenotic areas are characterized by an expansion of the media, caused by up to a 2.5-fold increased number of lamellar units (72), with relatively preserved organization of elastic lamellae and smooth muscle cells.

Three morphological types of SVAS are defined (74). Membranous SVAS is rare and consists of constricting semicircular valve-like membrane or membranes located at the sinotubular junction. The membrane contains small stellate cells in abundant mucopolysaccharide ground substance with few collagen and elastic fibrils but no medial elements (75). The second and third types of SVAS, the hourglass and diffuse types, share histological characteristics of disorganized lamellar architecture in the media, haphazard and fragmented elastic fibers, and focal clumping and hypertrophy of smooth muscle cells (Figure 4D) (75). In addition, enlargement of vasa vasoherum has also been observed in the media and adventitia. Focal mural induration is sometimes observed. These regions, in

Table 1
CV clinical findings in patients from nine selected series

<table>
<thead>
<tr>
<th>Clinical finding</th>
<th>Combined prevalence (%)</th>
<th>Range of prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any CV disease</td>
<td>84</td>
<td>53–100</td>
</tr>
<tr>
<td>SVAS</td>
<td>69</td>
<td>28–100</td>
</tr>
<tr>
<td>Pulmonary arterial stenosis</td>
<td>34</td>
<td>0–83</td>
</tr>
<tr>
<td>Hypertension</td>
<td>17</td>
<td>3–30</td>
</tr>
<tr>
<td>Mitral valve disease</td>
<td>15</td>
<td>4–43</td>
</tr>
<tr>
<td>Coarctation of aorta</td>
<td>4</td>
<td>0–19</td>
</tr>
<tr>
<td>Aortic hypoplasia&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>2</td>
<td>0–14</td>
</tr>
<tr>
<td>Pulmonary valve disease</td>
<td>5</td>
<td>0–47</td>
</tr>
<tr>
<td>Aortic valve disease</td>
<td>3</td>
<td>0–11</td>
</tr>
</tbody>
</table>

*<sup>a</sup>Ref. 36–44; n = 423; <sup>b</sup>Some patients had multiple abnormalities.

*<sup>c</sup>Range of prevalence for all series combined.

<sup>ab</sup>Severe diffuse hypoplasia, or abdominal coarctation.

Figure 3
Aortogram in a 4-year-old individual with WBS. SVAS (arrowhead) and mild narrowing of the proximal left main coronary artery (arrow) are shown. The gradient measured at catheterization was 40 mmHg.
addition to smooth muscle cells, have an extracellular matrix (Figure 4E) that is rich in mucopolysaccharides and contains endothelium-lined lacunae (74, 75).

**Elastin haploinsufficiency as a cause of CV disease**

_Familial SVAS and WBS_. As introduced earlier, understanding of the molecular basis of CV disease in WBS was aided by studies of a related but genetically distinct disease, familial SVAS (76). The spectrum, natural history, and pathological characteristics of CV and connective tissue lesions in patients with familial SVAS are virtually identical to those found in WBS. However, familial SVAS patients do not have neurobehavioral, metabolic, endocrine, developmental, or some of the craniofacial characteristics of WBS. These differences are due to the fact that familial SVAS is not a microdeletion syndrome but rather is caused by translocations (15), deletions (6, 16), and point mutations (77–79) that disrupt only the _ELN_ gene. Despite significant allelic heterogeneity, all _ELN_ mutations in familial SVAS studied to date cause loss of function at various levels of elastin biosynthesis, most commonly by eliminating the mutant mRNA via the nonsense-mediated decay pathway (79). Heterozygous loss-of-function mutations in familial SVAS and chromosomal deletion in WBS both cause reduced elastin synthesis and increased proliferation of cultured vascular smooth muscle cells and fibroblasts (73). Thus, both the clinical characteristics of, and the molecular mechanisms underlying, CV disease in WBS and familial SVAS appear to be the same and can be denoted by the term _elastin arteriopathy_ (11).

_Animal models_. Animal models provide further evidence for elastin haploinsufficiency as the main cause of CV disease in WBS. Mice homozygous for targeted inactivation of _Eln_ (+/−) show increased number and decreased thickness of lamellae (G and I) compared with control (+/+) (F and H). Reproduced from ref. 68. Knockout mice rescued by a human bacterial artificial chromosome transgene (−/−-BAC) (K) have only 30% of normal levels of elastin in the aorta, but thickness of the media is significantly increased relative to control (J). Reproduced with permission from _Circulation Research_ (81). Complete loss of elastin in homozygous knockout mice (−/−) (M) show neonatal obstructive disease of the aorta. Control aorta at postnatal day 0.5 shows robust elastin staining (L). Reproduced with permission from _Nature_ (80).

**Figure 4**

Vascular abnormalities in WBS and in animal models of elastin deficiency. Aortic sections from a 2-year-old healthy donor (A and C) and from an age-matched WBS patient with severe SVAS (B, D, and E) were stained with Movat’s pentachrome stain to visualize elastic lamellae (black). A nonstenotic segment of the WBS aorta shows relatively preserved lamellar architecture but greatly increased medial thickness (B). In the stenotic region, the lamellae in the media are fragmented (D) and a focal area of proliferation is observed on the intimal aspect of the vessel that accompanies some SVAS lesions, particularly those of the hourglass type (E). Original magnification, ×100 (A and B); ×400 (C–E). Reproduced from _American Journal of Human Genetics_ (73). Mice heterozygous for targeted inactivation of _Eln_ (+/−) show increased number and decreased thickness of lamellae (G and I) compared with control (+/+) (F and H). Reproduced from ref. 68. Knockout mice rescued by a human bacterial artificial chromosome transgene (−/−-BAC) (K) have only 30% of normal levels of elastin in the aorta, but thickness of the media is significantly increased relative to control (J). Reproduced with permission from _Circulation Research_ (81). Complete loss of elastin in homozygous knockout mice (−/−) (M) show neonatal obstructive disease of the aorta. Control aorta at postnatal day 0.5 shows robust elastin staining (L). Reproduced with permission from _Nature_ (80).
lamellar units are believed to normalize vessel wall strain (68). Both potential genetic modifiers, variants in explain all of the variability in CV disease expression. Among vascular caliber and perfusion, whereas the increased number of vascular compliance in of angiotensin II receptor blockers candesartan and salasar (68). Hypertension and increased number of lamellae are characteristic of the human and the animal model elastin arteriopathy. However, significantly reduced ELN expression compared with controls even after dating from infantile lethality to no overt or clinically apparent CV involvement. Male sex, a known significant risk factor, is associated with earlier onset and more severe disease (82) but does not explain all of the variability in CV disease expression. Among potential genetic modifiers, variants in ELN, in the size of the WBS critical region, in the “intact” alleles on the normal chromosome 7 homolog, and elsewhere in the genome need to be considered. Given that the developing vasculature is exquisitely sensitive to elastin dose (81), factors that influence elastin biosynthesis, including polymorphisms within ELN, are likely to have important effects on disease severity. Significant differences in elastin synthesis and cross-linking have been observed between different ethnic groups (83) suggesting a genetic basis for natural variation in elastin production. Expression of ELN has been studied in two WBS cohorts. One, enrolling only WBS patients with severe SVAS (73), found significantly reduced ELN expression compared with controls even after accounting for hemizygosity. In contrast, the second study detected normal ELN expression on average, though the authors noted high individual variability (84). Additionally, the second cohort showed a trend for higher ELN expression in patients without SVAS, but the difference did not reach statistical significance. These findings suggest that residual elastin expression protects against the development of CV disease in WBS, but adequately powered and controlled studies are needed to prove this point beyond doubt. Investigation of patients with intracranial aneurysms identified noncoding polymorphisms that affected the expression of ELN, identifying candidate risk alleles for elastin arteriopathy (85). Reduced expression of a few nondeletes genes mapping to the duplicons flanking the WBS critical region have been documented (84). Variations in the expression of these adjacent genes may be another factor contributing to the phenotypic differences in individuals with WBS. Among the genes within the WBS critical region, NCF1 dose has been associated with the prevalence of hypertension (18). The NCF1 gene (Figure 2) and two NCF1 pseudogenes, both inactivated by a GT dinucleotide deletion, are located in a telomeric block of low copy number repeats flanking the WBS critical region. In the general population, gene conversion events between the gene and the pseudogenes result in a natural variation of active NCF1 gene dose, ranging from 2 to 4 (86). In WBS patients, the deletion breakpoint determines whether the NCF1 gene is deleted (14), so that gene dose ranges from 1 to 4. In the WBS patients with more than one copy of NCF1, approximately 56% of the total WBS population, the risk of hypertension is increased 4-fold compared with those with only one functional NCF1 allele (18). NCF1 encodes the p47^{phox} subunit of the NADPH oxidase, and reduced angiotensin II-mediated oxidative stress in the vasculature is proposed as the mechanism responsible for this protective effect.

Mechanisms of obstructive vascular disease in WBS
Both human and animal studies suggest that elastin is required for the terminal differentiation and quiescence of vascular smooth muscle cells. In elastin-null mice, increased vascular smooth muscle cell proliferation both in vivo and in organ culture occur (80). This hyperproliferative phenotype was associated with decreased stress fiber and focal adhesion formation and increased vascular smooth muscle cell migration in vitro and was suppressed by treatment with tropoelastin, the soluble precursor protein of elastin (87). Similarly, both dermal fibroblasts and aortic smooth muscle cells isolated from patients with WBS or familial SVAS showed increased proliferation inversely proportional to the amount of elastin produced. Treatment of these cells with insoluble elastin normalized the hyperproliferative phenotype (73).

The formation of segmental obstructive lesions is thought to be a two-step process, consisting of increased number of lamellar units and vessel wall thickening during fetal development, leading to a

Figure 5
Proposed mechanisms of elastin signaling. (A) A 67-kDa EBP is thought to form a receptor complex with protective protein/cathepsin A (PP) and transmembrane sialidase/neuraminidase (Sase). Elastin peptide binding to the receptor activates the L-type Ca^{2+} channel and G-proteins (Gx, Gβ, γ) to activate the MAPK pathway (92). (B) A different pathway postulates a GPCR for tropoelastin. GPCR-elastin binding depresses cAMP levels by inhibiting adenylate cyclase (AC) and leads to increased actin polymerization through the Rho kinase pathway (87). (C) Cells can also sense the elastin content indirectly by binding to elastic fiber components such as fibrillins and fibulin-5 via integrins.
uniformly altered vascular tree, followed by postnatal injury-mediated inward remodeling (72). The preferential localization of segmental stenoses to the sinotubular junction and to branch points, areas of high turbulence, supports this notion. Interestingly, Eln+/– mice are protected from vascular remodeling following carotid artery ligation in the ipsilateral vessel while enhanced remodeling occurs in the contralateral artery (88), suggesting that elastin haploinsufficiency may differentially affect ligation-mediated and flow-mediated injury responses. Eln+/– mice show the same CV remodeling response in the renal artery clipping model of adult hypertension as do wild-type animals (89) but are protected from the age-related vessel wall thickening observed in wild-type animals (90). Further clinical studies are needed to determine whether patients with WBS are also protected from age-related vascular changes.

Although it is clear that elastin is a negative regulator of cell proliferation in development, the precise receptors and pathways mediating elastin signaling remain to be identified. Studies in different experimental systems yielded conflicting results. A specific 67-kD elastin-binding protein (EBP) localized to the cell surface has been identified as an enzymatically inactive, alternatively spliced Rho kinase, leading to increased actin polymerization (Figure 5B). Early morbidity and mortality associated with infantile hypercalcemia and hypertension (59) suggests a role for calcium channel blockade. Angiotensin receptor blockade may be challenging so that multidrug regimens may be required for adequate control of blood pressure. Patients with hypertension resistant to drug therapy should be studied for a renovascular etiology.

Future therapies
Surgical treatment of vascular lesions in WBS frequently relies on the use of vascular grafts, most commonly made of artificial materials such as polyethylene terephthalate (Dacron) or expanded polytetrafluoroethylene (ePTFE). The resilience, long-term stability, and cellular attachment properties of elastin make it an attractive material for this purpose. However, current approaches have not been successful in fully integrating elastin into the arterial wall. Eln−/− mice show exaggerated intima formation, as well as increased vascular cell proliferation and migration (88), providing in vivo evidence to support a role for fibulin-5 in elastin signaling. Better understanding of the pathways that connect elastin deficiency to increased vascular cell proliferation may help identify new targets for the treatment of CV disease in WBS.

Current treatment
The series from Table 1 describe operative or catheter-based interventions in 18% of patients for left ventricular outflow tract obstruction and in 4% of patients for right ventricular outflow tract obstruction (36–44). Patients with mild SVAS in infancy (peak catheterization gradient <20 mmHg) often remain stable and do not require intervention (36).

Operative techniques for repair of SVAS have utilized patch aortoplasty that may involve augmentation of 1–3 of the aortic sinuses (95, 96). The symmetric inverted 3-sinus patch plastic has resulted in improved outcome in one large series (49). Early mortality for repair of SVAS is 1%–9% (range of median or mean age at operation, 6–16 years), with 20-year survival of 77%–97% and long-term reduction in peak catheterization gradients in the majority of patients (36, 49, 95, 97). Although gradients maybe relieved, hypoplasia may persist in the remainder of the aortic arch (98). Diffuse hypoplasia of the aorta is a risk factor for reoperation (36, 49, 99). In patients with severe left main coronary obstruction, patch enlargement of the coronary or, excision of a fused aortic leaflet, and bypass grafting have been utilized (100).

Most patients with pulmonary arterial stenosis without significant SVAS can be observed without need for treatment in view of well-documented spontaneous improvement. For patients with persistent systemic or suprasystemic right ventricular pressure, marked asymmetry in pulmonary blood flow, or symptoms, balloon dilation angioplasty has been used to improve arterial diameter, especially in distal vessels. After catheter-based therapy, right ventricular pressure often remains elevated due to residual proximal obstruction, and the incidence of aneurysms is higher in comparison with non-WBS subjects (101). Patients with biventricular outflow obstruction with an indication for surgical relief of SVAS may undergo balloon angioplasty of pulmonary arterial stenosis prior to surgery. In a series of 33 patients with median age of operation of 4 years for biventricular obstruction, early mortality was 18% (96). Patients with middle aortic syndrome and long segment narrowing may undergo aorto-aortic bypass or patch plasty with bypass grafting of involved renal and visceral arteries (102). Catheter-based therapy is an option for some middle aortic lesions that are more localized (102).

Many patients require treatment for hypertension, but data are not available to recommend drug selection targeted for WBS. Beta blocker and calcium channel blocker drugs have been utilized frequently in several of the retrospective series (7, 40, 61, 103), and the link between infantile hypercalcemia and hypertension (59) suggests a role for calcium channel blockade. Angiotensin receptor blockade is effective in the Eln−/− mouse model. Medical treatment in WBS can be challenging so that multidrug regimens may be required for adequate control of blood pressure. Patients with hypertension resistant to drug therapy should be studied for a renovascular etiology.
(109) have been shown to upregulate elastin production in vivo. MMP inhibitors may be beneficial in preventing elastin degradation associated with vascular remodeling (110). A number of pulmonary vasodilatory drugs are efficacious in the treatment of primary pulmonary arterial hypertension, including calcium channel blockers, prostacyclin analogs, endothelin receptor antagonists, and NO agonists (111, 112). These agents could be evaluated as potential modulators of vascular lesions in WBS, even though the pathology of ELN arteriopathy is distinct from primary pulmonary arterial hypertension.

Nutritional intervention or nutraceuticals may theoretically be targets affecting elastin arteriopathy. Copper deficiency (113), β-aminopropionitrile (contained in certain legumes), and drugs such as amine oxide inhibitors and penicillamine (114) all inter- fer with the activity of lysyl oxidases, a family of enzymes required for elastin cross-linking (115). On the other hand, dill extract has been shown to increase LOXLI (lysyl oxidase like 1) gene expression and elastin deposition in vitro (116). Finally, ellagic and tannic acid (polyphenols found in berries and nuts) inhibit proteolytic degrada- tion of elastin and increase elastin deposition in skin fibroblast and organ cultures (117). It remains to be shown whether any of these natural products can reverse the effects of elastin deficiency in vivo.

Better understanding of the mechanisms behind the spontaneous improvement of pulmonary vascular lesions in WBS might lead to new treatment options. Developmental, physiological, mechani- cal, and biochemical differences between the pulmonary and sys- temic arterial trees need to be considered as potential mechanisms. Benign peripheral pulmonary stenosis is a common cause of inno- cent murmurs detected in the first month of life. The murmur and slightly elevated flow velocity are usually gone by 6–12 months of life (118, 119). Neonatal adaptation to breathing is known to in- volve a rapid increase in pulmonary flow, with a more gradual growth of the branch pulmonary arteries. One can speculate that this developmental adaptation may account for some of the resolu- tion of pulmonary stenotic lesions in infants with WBS.

Another potential therapeutic strategy involves targeted upregulation of a patient’s own genes, as has already been accomplished for HIF-1α in a patient with peripheral artery disease (120). Although approximately two dozen genes are deleted in WBS patients, their normal chromosome 7 homolog contains an intact copy of each allele. WBS is a particularly compelling model for this treatment approach, especially if transcriptional control of normal ELN gene splice variants can be retained (121, 122). An alternative approach to in situ gene therapy would involve genetic modification of autologous progenitor (or already differ- entiated) vascular cells ex vivo followed by re-introduction back into the affected individual, though the challenges of appropriate delivery and integration into sites of vascular lesions present a formidable challenge.

In summary, the insight that the vascular lesions in WBS are linked to hemizygosity of the ELN gene and the creation of an Eln knockout mouse with vascular pathology have provided a focus for connecting elastin biology with vascular disease. In order to translate experimental insights to treatments, newer animal models that better recapitulate the features of WBS may play an important part. For example a second-generation model with regulatable elastin expression in the vessel wall may resolve important questions such as whether re-expression of elastin, or administration of antiproliferative smooth muscle cell pharma- cotherapy, can reverse the disease process, especially in instances where vascular lesions have already formed. These efforts, along with continued research to elucidate pathophysiology and disease modifiers, will hopefully result in therapies that are alternatives to surgery in that they can ameliorate or even prevent the common complications of WBS arteriopathy.

Acknowledgments

This work was funded in part by NIH grant HL084922 and Ameri- can Heart Association grant 0655626Z, to Z. Urban. The authors gratefully acknowledge ongoing encouragement from the Chloe’s Quest Foundation and the Williams Syndrome Association.

Address correspondence to: Barbara R. Pober, MassGeneral Hospital for Children, Simches Research Building, Rm. 222, 185 Cambridge St., Boston, Massachusetts 02114, USA. Phone: (617) 726-1561; Fax: (617) 726-1566; E-mail: pober.barbara@mgh.harvard.edu.


dial multifocal cerebral arteriopathy in Williams syndrome. J. Pediatr. 126:945–948.


84. Merla, G., et al. 2006. Submicroscopic deletion in patients with Williams-Beuren syndrome influenc-
85. Akagawa, H., et al. 2006. A haplotype spanning two genes, ELN and LIMK1, decreases their transcripts and con-
gene not containing the signature GT deletion: significance for A77 degrees chronic granulomatous disease carrier detection. Blood. 100:1845–1851.
93. Spofford, C.M., and Chilian, W.M. 2001. The elastin-laminin receptor functions as a mechanotrans-
94. Loeys, B., et al. 2002. Homozygosis for a mis-
97. Brown, J.W., Ruzmetov, M., Vijay, P., and Tur-
100. Thistlethwaite, P.A., Madani, M.M., Kriett, J.M., Mil-
hoan, K., and Jamieson, S.W. 2000. Surgical man-

120. Rajagopalan, S., et al. 2007. Use of a constitutively 

erties, specificity, and biological roles inside and 

ences between main and branch pulmonary arteries in infants. Circulation. 45:410–419.
120. Rajagopalan, S., et al. 2007. Use of a constitutively 

121. Giordano, F.J. 2007. Therapeutic gene regulation: 

